

## Laniquidar TFA

### Chemical Properties


CAS No. :

Formula: C39H37F3N4O5

Molecular Weight: 698.73

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



### Biological Description

Description	Laniquidar TFA (R101933) is a novel orally available non-competitive P-glycoprotein (P-gp) inhibitor with an IC50 value of 0.51 $\mu$ M. Laniquidar has limited bioavailability and can be used to modulate the multidrug resistance transporter. Laniquidar can be used for the study of AML and myelodysplastic syndrome (MDS). Laniquidar is used to study acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Targets(IC50)	P-gp

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.4312 mL	7.1558 mL	14.3117 mL
5 mM	0.2862 mL	1.4312 mL	2.8623 mL
10 mM	0.1431 mL	0.7156 mL	1.4312 mL
50 mM	0.0286 mL	0.1431 mL	0.2862 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Luurtsema G, et al. Evaluation of [<sup>11</sup>C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol. 2009 Aug;36(6):643-9.
- Ross DD. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004 Dec;17(4):641-51.
- Fox E, et al. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481